Shares of Beigene Ltd (NASDAQ:BGNE) have been given a consensus rating of “Buy” by the ten analysts that are covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $93.00.

Several brokerages have recently commented on BGNE. Morgan Stanley reaffirmed an “overweight” rating and set a $95.00 price target (up previously from $87.00) on shares of Beigene in a research report on Friday, October 6th. Robert W. Baird reaffirmed a “neutral” rating and set a $83.00 price target (up previously from $58.00) on shares of Beigene in a research report on Tuesday, November 14th. Maxim Group reaffirmed a “buy” rating and set a $120.00 price target (up previously from $77.00) on shares of Beigene in a research report on Thursday, September 28th. Zacks Investment Research raised shares of Beigene from a “hold” rating to a “buy” rating and set a $115.00 price target on the stock in a research report on Tuesday, October 3rd. Finally, Cowen reaffirmed a “buy” rating on shares of Beigene in a research report on Monday, December 11th.

In other Beigene news, CEO John Oyler sold 150,957 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $80.50, for a total value of $12,152,038.50. Following the transaction, the chief executive officer now owns 491,891 shares of the company’s stock, valued at $39,597,225.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CMO Amy C. Peterson sold 3,601 shares of the firm’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $82.96, for a total transaction of $298,738.96. Following the completion of the transaction, the chief marketing officer now directly owns 1,201 shares in the company, valued at approximately $99,634.96. The disclosure for this sale can be found here. Insiders have sold 483,482 shares of company stock worth $42,139,474 in the last ninety days. Corporate insiders own 19.90% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of BGNE. Renaissance Technologies LLC bought a new position in Beigene in the first quarter worth about $238,000. First Trust Advisors LP lifted its holdings in Beigene by 2.2% in the second quarter. First Trust Advisors LP now owns 48,860 shares of the company’s stock worth $2,199,000 after acquiring an additional 1,029 shares during the last quarter. SG Americas Securities LLC bought a new position in Beigene in the second quarter worth about $111,000. Myriad Asset Management Ltd. lifted its holdings in Beigene by 16.6% in the second quarter. Myriad Asset Management Ltd. now owns 385,585 shares of the company’s stock worth $17,351,000 after acquiring an additional 54,900 shares during the last quarter. Finally, Alliancebernstein L.P. bought a new position in Beigene in the second quarter worth about $7,373,000. 55.32% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Beigene (BGNE) traded down $1.87 during trading on Monday, hitting $98.52. The stock had a trading volume of 152,700 shares, compared to its average volume of 199,006. The company has a quick ratio of 9.27, a current ratio of 9.33 and a debt-to-equity ratio of 0.20. The firm has a market capitalization of $4,564.43, a P/E ratio of -75.78 and a beta of -1.03. Beigene has a 12 month low of $30.02 and a 12 month high of $118.95.

Beigene (NASDAQ:BGNE) last issued its quarterly earnings results on Monday, November 13th. The company reported $2.54 EPS for the quarter, topping the consensus estimate of $0.23 by $2.31. The company had revenue of $220.21 million for the quarter, compared to the consensus estimate of $1.55 million. During the same period in the previous year, the business posted ($1.08) EPS. sell-side analysts expect that Beigene will post -2.04 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This news story was reported by Marea Informative and is the property of of Marea Informative. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.mareainformativa.com/beigene-ltd-bgne-receives-93-00-average-target-price-from-analysts-updated-updated-updated/124713/.

Beigene Company Profile

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.

Analyst Recommendations for Beigene (NASDAQ:BGNE)

Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.